retatrutide news today recency 3 produces up to 30.3% weight loss in Phase trial Lilly's triple agonist, retatrutide, successful

A recent study raises questions about whether GLP-1 drugs like Ozempic and Mounjaro actually increase thyroid cancer risks, indicating that previously suggested associations may be the result of more intensive screening, rather than side effects the drugs have on the body

By activating GLP-1 receptors in the brain, these medications help you feel satisfied with smaller portions, making it easier to eat fewer calories

Results are noticeable within a few weeks, and multiple sessions may be recommended for optimal results

Funding No funding was obtained for this study

In clinical trials with semaglutide injection for type 2 diabetes mellitus (T2DM), 32 (1%) of patients receiving semaglutide tested positive for anti-semaglutide antibodies